BMS’s Opdivo and Yervoy colorectal cancer trials show promising results
![](https://drhimanshuyadav.com/wp-content/uploads/2024/01/BMSs-Opdivo-and-Yervoy-colorectal-cancer-trials-show-promising-results-1024x683.jpg)
BMS presented this data supporting the use of immune checkpoint inhibitors (ICIs) in combination in patients with newly diagnosed advanced colorectal cancer subtypes at the ASCO Gastrointestinal Cancer Symposium. Credit: Tada Images / Shutterstock. On January 22, BMS announced encouraging findings from the CheckMate -8HW clinical trial, showing that the combination of Opdivo (nivolumab) and […]
BMS’ Opdivo regimen shows promise in colorectal cancer clinical trials
![](https://drhimanshuyadav.com/wp-content/uploads/2024/01/BMS-Opdivo-regimen-shows-promise-in-colorectal-cancer-clinical-trials-1024x576.jpg)
BMS’ Opdivo plus Yervoy significantly improved progression-free survival in patients with MSI-H/dMMR metastatic colorectal cancer. Credit: Bristol-Myers Squibb Company. bristol myers squib (BMS) is a Phase III CheckMate-8HW clinical trial combining Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment option for microsatellite-high instability (MSI-H) or mismatch repair deficiency (dMMR). reported promising data. Metastatic colorectal […]
BMS Demonstrates Rationale for Opdivo and Yervoy Combination Therapy in First-Line Colorectal Cancer
![](https://drhimanshuyadav.com/wp-content/uploads/2023/12/BMS-Demonstrates-Rationale-for-Opdivo-and-Yervoy-Combination-Therapy-in.jpeg)
Photo: California BMS Building Exterior/iStock, hapa bapa Bristol-Myers Squibb on Thursday announced data from the Phase 3 CheckMate-8HW study demonstrating first-line potential for Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy in metastatic colorectal cancer. . BMS did not provide specific data in Thursday’s announcement, but the company said the combination therapy showed “statistically significant results” […]
BMS’s Opdivo meets co-primary endpoint in colorectal cancer trial
![](https://drhimanshuyadav.com/wp-content/uploads/2023/12/BMSs-Opdivo-meets-co-primary-endpoint-in-colorectal-cancer-trial.jpg)
Despite Opdivo’s success in combination trials, Bristol-Myers Squibb faces challenges as Opdivo’s European and U.S. patents expire in 2026 and 2028, respectively, threatening sales growth. There is. Credit: Dennis Diatel, via ShutterStock. Bristol-Myers Squibb (BMS) announced that its Phase III CheckMate-8HW study of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of metastatic […]